BRCA1 and breast carcinoma: The BRCA1/2 mutated patients belong to a group that already contains a high number of triple negative and basal-like breast cancers [37], but here we showed that triple negative tumors in BRCA1/2 mutated carriers are even more highly expressing ANXA1 than triple negative patients in the BCAC cohort (Fig. 1).